News
BFRI
2.870
+4.36%
0.120
Biofrontera Highlights Data From American Cancer Society As It Applies To Co.'s Ameluz Drug; BZ NOTE: This Type Of News Item Does Not Frequently Move Stocks
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1, indicating
Benzinga · 2d ago
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1...
GlobeNewswire · 2d ago
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private plac...
GlobeNewswire · 05/19 13:48
BRIEF-Biofrontera Inc Announces Pricing Of $9.4 Million Private Placement
reuters.com · 05/16 12:18
Biofrontera Prices ~3.4M Share Offering Of Common Stock, Warrant At $2.75/Unit
Biofrontera, Inc. (NASDAQ:BFRI, BFRIW)), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common
Benzinga · 05/16 12:14
Biofrontera prices $9.4M securities offering
Biofrontera (NASDAQ:BFRI) has priced its $9.4M private offering of shares and warrants. The offering consists of 3,419,000 shares of common stock and warrants to purchase up to an aggregate of
Seekingalpha · 05/16 12:13
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (o...
GlobeNewswire · 05/16 12:00
RIOT, MARA and DM among pre market gainers
Robinhood Markets (HOOD) +23% Bitcoin rebounds with rally above $30,000, but concerns remain. Endeavor Group Holdings (EDR) +20% on Q1 results. Molecular Partners (MOLN) +19% on Q1 results. Celularity (CELU) +18%. Coinbase Global (COIN) +14% Robinhood Mark...
Seekingalpha · 05/13 12:32
BRIEF-Biofrontera Reports Q1 Revenue Rose 106%
reuters.com · 05/13 11:35
Biofrontera GAAP EPS of $0.32 beats by $0.48, revenue of $9.8M misses by $0.03M
Biofrontera press release (NASDAQ:BFRI): Q1 GAAP EPS of $0.32 beats by $0.48. Revenue of $9.8M (+106.3% Y/Y) misses by $0.03M.
Seekingalpha · 05/13 11:31
Biofrontera Q1 EPS $0.32 Up From $(0.44) YoY, Sales $9.75M Miss $9.90M Estimate; Reaffirms Guidance
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.32 per share. This is a 172.73 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $9.75
Benzinga · 05/13 11:07
Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today ann...
GlobeNewswire · 05/13 11:00
-- Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT Newswires · 05/13 07:03
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before th...
GlobeNewswire · 05/06 12:25
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education
Live Demonstration of New RhodoLED® XL to be Featured WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsor...
GlobeNewswire · 05/05 12:30
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
Ameluz® for the treatment of actinic keratoses now at www.ameluz.comXepi® for the treatment of impetigo now at www.xepicream.com WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in...
GlobeNewswire · 04/21 17:20
Natus Medical, MedAvail top healthcare gainers; Nektar, TG Therapeutics lead losers' pack
Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%. Biofronter...
Seekingalpha · 04/18 14:00
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
Benzinga · 04/18 09:21
Peering Into Biofrontera Inc. - Common Stock's Recent Short Interest
Biofrontera Inc. - Common Stock's (NASDAQ:BFRI) short percent of float has risen 6.56% since its last report. The company recently reported that it has 821.90 thousand shares sold short, which is 15.93% of all regular shares that are available for trading.
Benzinga · 04/14 19:11
VSTM, ZY and SGLY among mid-day movers
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain
Seekingalpha · 04/14 16:29
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.